Table of Contents
Introduction
Global Structural Heart Devices Market size is expected to be worth around USD 32.2 Billion by 2032 from USD 13.7 Billion in 2023, growing at a CAGR of 10.3% during the forecast period from 2024 to 2032.
Structural heart disease encompasses non-coronary heart defects that don’t impact the heart’s blood vessels. While many of these conditions are congenital, appearing at birth, others may develop later in life through infection or general wear and tear. Recent medical advancements have shifted treatment from traditional open-heart surgery to less invasive methods like transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR).
The market for structural heart devices is primarily driven by an increase in structural heart disease cases such as aortic stenosis and mitral regurgitation, alongside significant technological advancements and the creation of innovative repair devices like annuloplasty rings and occluders. There’s also a growing preference for minimally invasive procedures.
However, factors like the high cost of these surgeries and strict regulatory environments pose challenges to market growth. Despite these challenges, the focus of key players on research and development of new structural heart devices and rising demand for efficient, long-term treatments among aging populations are creating new opportunities in the sector.
According to Children’s HeartLink reports that 1% of infants are born with congenital heart disease (CHD), a condition stemming from structural heart anomalies. In regions equipped with specialized pediatric cardiac care, the majority of these infants thrive into adulthood. However, approximately 90% of affected children worldwide lack access to necessary treatment due to its unavailability or prohibitive cost. To address this disparity, Children’s HeartLink focuses on empowering local pediatric heart teams through training in countries such as Bangladesh, Brazil, China, India, Malaysia, and Vietnam, aiming to enhance the accessibility and affordability of care for these vulnerable populations.
Key Takeaways
- Market Size: Global Structural Heart Devices Market size is expected to be worth around USD 32.2 Billion by 2032 from USD 13.7 Billion in 2023.
- Market Growth: The market growing at a CAGR of 10.3% during the forecast period from 2024 to 2032.
- Product Analysis: During the forecast period, the heart valve devices segment is expected to hold the highest share of 34%.
- Indication Analysis: The aortic valve stenosis segment accounted for the highest revenue share of 25% in 2022.
- Procedure Analysis: The replacement procedures segment is estimated to account for the largest market share of 39% during the forecast period.
- End-Use Analysis: The hospitals segment dominate the market in 2023.
- Regional Analysis: North America held the dominant revenue share of 45.3% for the global structural devices market.
Structural Heart Devices Statistics
- Cardiovascular Disease Impact and Costs
- Cardiovascular diseases (CVDs) were responsible for 928,741 deaths in the United States in the year 2020.
- Among CVD deaths in 2020, coronary heart disease was predominant, accounting for 41.2% of the total.
- Strokes represented 17.3% of all CVD-related deaths.
- Other cardiovascular conditions accounted for 16.8% of the deaths due to CVDs.
- The cost related to cardiovascular diseases in the U.S., covering both direct healthcare expenses and lost productivity, amounted to $407.3 billion between 2018 and 2019.
- Risk Factors and Prevention
- Tobacco use led to approximately 8.09 million deaths globally in 2020.
- In the United States, secondhand smoke exposure increased risks of total mortality by 18% and cardiovascular mortality by 23%.
- A significant portion of U.S. high school students (23.6%) were found to be using tobacco products in 2020.
- Physical inactivity remained a concern with 25.4% of U.S. adults not engaging in any leisure-time physical activity in 2018.
- Dietary Trends and Their Impact
- There was an improvement in the mean American Heart Association healthy diet score among adults, decreasing the prevalence of poor diets from 56.0% to 47.7% between 2003 and 2016.
- Notable dietary changes included increased consumption of whole grains and nuts/seeds/legumes and decreased intake of sugar-sweetened beverages and processed meat during the same period.
- Despite improvements, significant nutritional disparities persisted among underrepresented racial and ethnic groups and those with lower socioeconomic status.
Emerging Trends
- 3D Printing of Heart Replicas for Pre-Surgical Planning: Researchers at MIT have developed a 3D-printed biorobotic hybrid heart, which can mimic the mechanical actions of a human heart. This innovation aids in pre-surgical planning and the customization of treatments for patients with complex heart conditions, ensuring interventions are tailored to individual anatomical and physiological needs.
- Cardiac Regeneration Using Stem Cells: The Mayo Clinic is pioneering efforts in cardiac regeneration, utilizing stem cells and cell-free therapies to repair irreversibly damaged heart tissue. This approach focuses on restoring function and promoting the growth of new cardiac cells, offering hope for patients who have previously had limited treatment options.
- Advanced Diagnostics and Portable Monitoring: The Ohio State University emphasizes the use of comprehensive diagnostic tools including echocardiograms and portable monitoring devices like the Holter monitor. These devices are critical in detecting irregular heart rhythms and assessing heart function, facilitating early intervention.
- Expansion of Minimally Invasive Procedures: There’s a growing shift towards minimally invasive procedures in structural heart interventions. Techniques such as Transcatheter Aortic Valve Replacement (TAVR) are becoming more common, reducing recovery times and risks associated with open heart surgery.
- Integration of Artificial Intelligence in Diagnostic Processes: AI and machine learning are increasingly being integrated into the diagnostic process, enhancing the precision of heart imaging and the prediction of patient outcomes. This technology helps in identifying the most effective treatment approaches based on predictive analytics.
- Focus on Personalized Medicine: Personalized medical approaches are being developed to treat structural heart issues, which consider a patient’s unique genetic profile and disease trajectory. This trend is driven by the broader adoption of genomic medicine and targeted therapies in cardiology.
- Regenerative Medicine Therapeutic Suites: Facilities dedicated to regenerative medicine, like those at the Mayo Clinic, are focusing on developing therapies that can regenerate heart tissues and potentially reduce the need for heart transplants.
- Use of Biocompatible Materials in Device Manufacturing: The evolution of material science has led to the development of more durable and biocompatible materials for heart valves and other structural heart devices, improving patient compatibility and device longevity.
Use Cases
- Percutaneous Valve Replacement and Repair: Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of severe aortic stenosis, especially for patients deemed at high or prohibitive surgical risk. This minimally invasive procedure replaces the aortic valve without the need for open-heart surgery, significantly reducing recovery time and improving patient outcomes.
- Ventricular Assist Devices (VADs): VADs support heart function and blood flow in patients with weakened hearts or heart failure. These devices are crucial for patients waiting for a heart transplant or as a long-term solution in cases where heart transplantation isn’t an option. They have significantly improved survival and quality of life for patients with advanced heart failure.
- Closure of Septal Defects: Devices like occluders are used to close defects such as patent foramen ovale (PFO) and atrial or ventricular septal defects. These procedures prevent the mixing of oxygenated and deoxygenated blood within the heart, which can lead to stroke and heart failure if untreated.
- Automated External Defibrillators (AEDs): AEDs are critical in treating sudden cardiac arrest in community settings. These devices analyze the heart’s rhythm and can deliver an electric shock to restore normal rhythm during cardiac emergencies. AEDs are designed for use by the public, requiring minimal training.
- Heart Valve Disease Management: For patients with heart valve diseases such as stenosis or regurgitation, structural heart devices can repair or replace faulty valves. This relieves symptoms like fatigue and weakness, prevents heart failure, and improves overall heart function.
- Advanced Diagnostic and Monitoring Tools: Structural heart programs integrate advanced imaging and diagnostic technologies to assess and monitor heart function. This comprehensive approach allows for precise treatment planning and real-time adjustment of therapies.
- Management of Cardiac Complications from COVID-19: The pandemic highlighted the cardiovascular impact of COVID-19, with many patients experiencing myocardial injuries from microvascular clots. Structural heart devices play a role in managing these complications, particularly in patients with severe inflammatory responses.
- Cardiac Rehabilitation Devices: Post-treatment cardiac rehabilitation is essential for recovery and long-term health. Devices and programs tailored to rehabilitate heart patients can monitor recovery, provide necessary adjustments in therapy, and ensure patients return to health safely.
Conclusion
The structural heart devices market is poised for significant expansion, driven by an increasing prevalence of structural heart diseases, technological advancements, and a shift towards minimally invasive procedures. Despite challenges like high costs and stringent regulations, opportunities abound due to ongoing research and development and the rising demand for effective treatments among aging populations. With innovations like 3D-printed heart replicas and stem cell therapies enhancing pre-surgical planning and patient-specific treatments, the market is expected to grow robustly. North America remains a dominant force, with substantial growth projected globally, underlining the sector’s potential for transformative impact on cardiac care.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
